What is monobenzone, and what is the goal?
Monobenzone, historically sold in the United States as Benoquin, is a topical medicine intended to remove remaining pigment in extensive vitiligo. It is not a repigmentation treatment or cosmetic skin lightener, and its mechanism is not fully understood; it may destroy melanocytes and cause permanent change beyond treated skin. Evidence
Why this matters
The archived label describes final depigmentation for people with extensive disseminated idiopathic vitiligo. The goal is a more uniform loss of remaining color, not a test of whether pigment can return.
Questions for a depigmentation specialist
- Am I seeking repigmentation, camouflage, acceptance support, or permanent removal of remaining pigment?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Why is monobenzone being discussed for my situation?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is monobenzone approved and available where I live?
Benoquin retains a historical US approval record for final depigmentation, but FDA review material says the branded product is no longer manufactured or distributed. A compounded monobenzone preparation is not FDA-approved. SteadySkin did not verify one central EU authorization or a current UK licensed product, and national status may differ. Evidence Evidence Evidence Evidence Evidence
Why this matters
Approval, current manufacturing, commercial distribution, compounding, special access, and prescribing are different facts. The central EU register also cannot settle every member-state authorization by itself.
Questions for a depigmentation specialist
- Who made this exact preparation?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Is it an approved commercial product, a compounded medicine, or an unlicensed special?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Who verifies its identity and quality?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What evidence is there that final depigmentation works?
The outcome evidence is sparse and old. In a retrospective series of 18 people with severe vitiligo, 8 were reported as completely depigmented and 3 as having dramatic but incomplete depigmentation; complications were frequent. This uncontrolled series cannot predict a uniform result or compare monobenzone fairly with other paths. Evidence
Why this matters
The small series suggests that substantial or complete change can occur and that some people who fully depigmented reported high satisfaction. It also reports frequent complications and large variation.
Questions for a depigmentation specialist
- How strong is the evidence for the result I want?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What does the evidence not report about skin tone, body sites, identity, and long-term outcomes?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would count as an unacceptable or uneven result for me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can change permanently, distantly, or unpredictably?
The historical label limits monobenzone to final depigmentation in disseminated idiopathic vitiligo affecting more than half of body surface. It lists use for another condition and prior sensitivity or allergy to the product or its ingredients as contraindications. Monobenzone can cause irreversible, irregular, excessive, distant, or cosmetically unacceptable depigmentation, along with irritation, burning, eczema, and sensitization. The archived label also leaves long-term cancer risk and several pregnancy, breastfeeding, and pediatric questions unresolved; successful depigmentation creates lifelong sun-sensitivity considerations. Evidence
Why this matters
The historical label limits this medicine to final depigmentation in disseminated idiopathic vitiligo affecting more than half of body surface. It contraindicates use for another condition and use after prior sensitivity or allergy to the product or its ingredients. The risk is not limited to temporary irritation: pigment loss can extend beyond where the medicine is placed, and the final appearance may not be even or acceptable.
Questions for a depigmentation specialist
- What areas could change even if they are not treated?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would we do if change is uneven or distressing?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What lifelong sun protection would become part of my life?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does compounded-product uncertainty mean?
Current US access may depend on a compounding pharmacy, which adds source, formulation, quality, availability, and cost uncertainty. A prescription and a familiar product name do not mean FDA reviewed the compounded preparation before use. Evidence Evidence
Why this matters
FDA does not pre-review a compounded drug for safety, effectiveness, or quality. The prescriber and pharmacy should be able to explain the ingredient source, formulation, testing, storage, labeling, contact route, and what happens if a problem is suspected.
Questions for a depigmentation specialist
- Which pharmacy and ingredient source are involved?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What quality records can be verified independently?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What happens if the appearance, texture, supply, or reaction changes between fills?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if a procedure or another medicine is proposed too?
Expert recommendations discuss procedures for resistant remaining pigment. But the reviewed evidence does not establish a standardized or predictably safe combination with lasers, freezing procedures, retinoids, or other agents. A proposed combination needs its own evidence and specialist plan. Evidence Evidence
Why this matters
A specialist may discuss a procedure for areas that retain pigment, but evidence for one component does not establish the safety or benefit of the exact combination. More aggressive does not mean more predictable.
Questions for a depigmentation specialist
- Has this exact combination been studied?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which component is expected to add what?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What new permanent risks or recovery burdens does it add?Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do identity, support, alternatives, and lived experience fit?
A permanent appearance change can affect identity, culture, family, safety, grief, and relief in ways a study cannot score for you. Lived experience can help name those realities, but it cannot remove the possibility of regret, uneven change, distant depigmentation, or later pigment return. Evidence Evidence
Why this matters
There is no moral duty to repigment, depigment, cover, uncover, or stop caring. A person can feel relief and grief together. Darker-skin, racial, cultural, family, safety, work, dating, and belonging concerns deserve explicit space before an irreversible choice.
Questions for a depigmentation specialist
- What nonpermanent alternatives remain available?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Can I speak with a mental-health professional who understands visible difference and identity?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- How will the team support me if I pause, decline, or later feel differently?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Questions that can change the next decision
- For your specialistIs the exact product licensed, manufactured, or compounded?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your specialistWhat could change permanently, distantly, or unevenly?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your support teamWhat identity and psychological support is available before I decide?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence snapshot
The regulatory record establishes a permanent-depigmentation boundary; outcome evidence is a small historical uncontrolled series, not modern comparative proof.
- Purpose
- Historical final-depigmentation indication for disseminated idiopathic vitiligo affecting more than half of body surface, not repigmentation.
- Outcome study
- Retrospective series of 18 people with limited modern reporting.
- Availability
- Historical approval and current branded-product availability are separate facts.
- Quality
- A compounded preparation is not FDA-approved or pre-reviewed for quality.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
The outcome evidence is sparse and old. In a retrospective series of 18 people with severe vitiligo, 8 were reported as completely depigmented and 3 as having dramatic but incomplete depigmentation; complications were frequent. This uncontrolled series cannot predict a uniform result or compare monobenzone fairly with other paths.
- Age range
- Not reported
- Condition subtype
- Severe vitiligo.
- Severity or extent
- Severe or extensive vitiligo.
- Sample size
- 18 people in a retrospective case series.
- Geography and care setting
- Not reported
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- Not reported
What that means for this page: The uncontrolled historical series is too small and poorly reported for a reliable modern success rate, body-site estimate, comparison, long-term safety conclusion, or individual prediction.
The historical label limits monobenzone to final depigmentation in disseminated idiopathic vitiligo affecting more than half of body surface. It lists use for another condition and prior sensitivity or allergy to the product or its ingredients as contraindications. Monobenzone can cause irreversible, irregular, excessive, distant, or cosmetically unacceptable depigmentation, along with irritation, burning, eczema, and sensitization. The archived label also leaves long-term cancer risk and several pregnancy, breastfeeding, and pediatric questions unresolved; successful depigmentation creates lifelong sun-sensitivity considerations.
- Age range
- Not reported
- Condition subtype
- Not reported
- Severity or extent
- Not reported
- Sample size
- Not reported
- Geography and care setting
- Not reported
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- Not reported
What that means for this page: The archived label establishes material hazards and unknowns for the historically approved product. It does not quantify personal risk, establish the quality of a compounded preparation, or resolve modern long-term evidence gaps.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The product company authored the prescribing information hosted by FDA. It is authoritative for the historical label but not independent clinical evidence.
What this source supports
Supports the historical US indication for final depigmentation in extensive disseminated idiopathic vitiligo, the purpose and mechanism limits, permanence and distant-depigmentation warnings, listed reactions, contraindication boundary, and long-term unknowns. Re-read in full on 2026-08-21 for what it states about sun, which is in three places. Under Precautions, General, it states that following therapy with the cream the skin will be sensitive for the rest of the patient’s life, and that the person must use sunscreens during exposure to the sun. Under Clinical Pharmacology it states that exposure to sunlight reduces the depigmenting effect of the drug. The same section states that the histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo, the epidermis being normal except for the absence of identifiable melanocytes. Under Dosage and Administration it states that prolonged exposure to sunlight should be avoided during treatment, or that a sunscreen should be used. Under Carcinogenesis, mutagenesis, impairment of fertility it states that no long term studies have been performed to evaluate carcinogenic potential.
What it does not support
The archived label does not establish current commercial availability, approval of a compounded preparation, predictable uniform results, suitability, a personal plan, or current status outside the US. Its sun statements are the label instructing a patient under a prescriber; SteadySkin reports them as the label’s wording and issues none of them as advice. It sets no sun protection factor, no interval and no exposure limit, and it measures nothing about how depigmented skin behaves in sunlight beyond the sensitivity statement itself. Because it performed no long term carcinogenicity study, it establishes nothing about skin cancer risk after depigmentation in either direction. The document carries a printed revision of August 2000 and an FDA banner stating it may not be the latest approved label, so it is used only for what it plainly states and never as current guidance.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the distinction between Benoquin’s retained historical approval record and the FDA-reviewed statement that the branded product was no longer manufactured or distributed and its structured label had been delisted.
What it does not support
It does not establish present inventory, lawful access for one person, the quality of any compounded preparation, or status outside the US.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the general US boundary that compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality before marketing.
What it does not support
It does not determine whether compounding is appropriate or lawful in an individual case, assess a particular pharmacy, or establish the quality of a particular monobenzone preparation.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Mosher DB, Parrish JA, Fitzpatrick TB)Observational study · Supporting research, tier 3Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports only the reported outcomes, complications, and satisfaction observations in a retrospective series of 18 people using monobenzyl ether of hydroquinone for final depigmentation.
What it does not support
The very small uncontrolled series cannot establish a predictable success rate, body-site response, long-term safety, comparison with other paths, or an individual outcome.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- European CommissionRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that nationally authorised medicine status is held in member-state registers and cannot be inferred solely from absence in the central Union Register.
What it does not support
It does not establish monobenzone approval, availability, prescribing, compounding, or reimbursement in any particular member state.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.